Assessment of platelet activation in myeloproliferative disorders with complementary techniques [PDF]
, 2004 Emilsé Bermejo +3 more
openalex +1 more source
Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders. [PDF]
Clin Appl Thromb Hemost, 2018 Yildiz A +5 more
europepmc +1 more source
Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression
, 2002 Oliver Bock +5 more
openalex +1 more source
GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder [PDF]
, 2005 Emily Carpenter +6 more
openalex +1 more source
On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense [PDF]
, 2005 Kenneth Kaushansky
openalex +1 more source
Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia [PDF]
, 2005 Dennis P. O’Malley +3 more
openalex +1 more source
Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders [PDF]
, 2006 Marianna Dávid +23 more
openalex +1 more source
Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders. [PDF]
J Natl Compr Canc Netw, 2017 McFarland DC +6 more
europepmc +1 more source
Clinical and disease characteristics from REVEAL at time of enrollment (baseline): Prospective observational study of patients with polycythemia vera in the United States [PDF]
, 2018 Boccia, Ralph V +7 more
core +1 more source
Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International Context [PDF]
, 2016 Harrison, Claire, McMullin, Mary Frances
core +1 more source